Effects of exendin-4 alone and with peptide YY3-36 on food intake and body weight in diet-induced obese rats

Obesity

Volumn 19, Issue 1, 2011, Pages 121-127

  Reidelberger, Roger D ^a,b   Haver, Alvin C ^a,b   Apenteng, Bettye A ^b   Anders, Krista L ^b   Steenson, Sharalyn M ^b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; PEPTIDE YY; PEPTIDE YY (3 36); PEPTIDE YY [3-36]; VENOM;

ANIMAL; ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EATING; FOOD INTAKE; LOW DRUG DOSE; MALE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RECEPTOR DOWN REGULATION; ROUX Y ANASTOMOSIS; SPRAGUE DAWLEY RAT; STOMACH BYPASS; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; EATING; HYPOGLYCEMIC AGENTS; MALE; OBESITY; PEPTIDE YY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; VENOMS; WEIGHT LOSS;

RATTUS;

EID: 78650677674     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.136     Document Type: Article

References (33)

1. Grady EF, Böhm SK, Bunnett NW. Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol 1997;273:G586-G601.
2. Morley JE, Flood J F. An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice. Life Sci 1987;41:2157-2165.
3. Salvà Lacombe P, García Vicente JA, Costa Pagès J, Lucio Morselli P. Causes and problems of nonresponse or poor response to drugs. Drugs 1996;51:552-570.
4. Reidelberger RD, Haver AC, Chelikani PK, Buescher JL. Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol 2008;295:R449-R458.
5. Chelikani PK, Haver AC, Reidelberger RD. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007;293: R1798-R1808.
6. Chelikani PK, Haver AC, Reidelberger RD. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 2007;293:R39-R46.
7. Chelikani PK, Haver AC, Reeve JR Jr, Keire DA, Reidelberger RD. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 2006;290:R298-R305.
8. le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780-785.
9. Korner J, Inabnet W, Febres G et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009;33:786-795.
10. Thorens B, Porret A, Bühler L et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993;42:1678-1682.
11. Amblard M, Fehrentz JA, Martinez J, Subra G. Methods and protocols of modern solid phase Peptide synthesis. Mol Biotechnol 2006;33:239-254.
12. Novelli EL, Diniz YS, Galhardi CM et al. Anthropometrical parameters and markers of obesity in rats. Lab Anim 2007;41:111-119.
13. Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155-E161.
14. Drucker DJ, Buse JB, Taylor K et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250.
15. Buse JB, Rosenstock J, Sesti G et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
16. Nauck M, Frid A, Hermansen K et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
17. Mack CM, Moore CX, Jodka CM et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006;30:1332-1340.
18. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005;146:3748-3756.
19. Raun K, von Voss P, Gotfredsen CF et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007;56:8-15.
20. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530-2539. (Pubitemid 33642771)
21. Scott KA, Moran TH. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007;293:R983-R987.
22. Quinn R. Comparing rat's to human's age: how old is my rat in people years? Nutrition 2005;21:775-777.
23. Neary NM, Small CJ, Druce MR et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005;146: 5120-5127.
24. Suzuki S, Ramos EJ, Goncalves CG, Chen C, Meguid MM. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery 2005;138:283-290.
25. Bueter M, Löwenstein C, Ashrafian H et al. Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass. Obes Surg 2010;20:616-622.
26. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 2010;151:1588-1597.
27. Blevins JE, Chelikani PK, Haver AC, Reidelberger RD. PYY(3-36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats. Peptides 2008;29:112-119.
28. Roth JD, Coffey T, Jodka CM et al. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 2007;148:6054-6061.
29. Roth JD, Trevaskis JL, Wilson J et al. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Int J Obes (Lond) 2008;32:1201-1210.
30. Trevaskis JL, Lei C, Koda JE et al. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity (Silver Spring) 2010;18:21-26.
31. Trevaskis JL, Coffey T, Cole R et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008;149:5679-5687.
32. Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 2000;8:317-323.
33. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002;60(10 Pt 2):S1-S14; discussion S68-S84, S85-S87.